4.7 Article

The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy:: A prospective international multi-center study

Journal

RADIOTHERAPY AND ONCOLOGY
Volume 80, Issue 2, Pages 123-131

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2006.07.010

Keywords

tumour oxygenation; hypoxia marker; pimonidazole; uterine cervix carcinoma

Funding

  1. NCI NIH HHS [CA37879] Funding Source: Medline
  2. PHS HHS [74069] Funding Source: Medline

Ask authors/readers for more resources

Background and purpose: Hypoxia adversely affects treatment outcome in human uterine cervical cancer. Here, we present the results of a prospective international multi-centre study evaluating the prognostic value of pre-treatment tumour oxygen partial pressure (pO(2)) and the hypoxia marker pimonidazole (pimo). Materials and methods: One hundred and twenty-seven patients with primary cervix cancer were entered. Pretreatment tumour pO(2) measurements were obtained, and reported by the median tumour pO(2), the fraction Of pO(2) values <= 10 mmHg (HP(10)), <= 5 mmHg (HP(5)) and <= 2.5 mmHg (HP(2.5)). Following intravenous pimonidazole administration, biopsies were taken, stained for pimonidazole adducts, and scored for the area of labelled tumour cells on a scale from 0 to 4. Treatment modalities were surgery (11%), radiotherapy (98%), chemotherapy (33%) and carbogen (14%). Results: None of the hypoxia descriptors were statistically significant prognostic factors for loco-regional tumour control or overall survival when analyzed as continuous variables or divided by the sample median. By univariate analysis only tumour size and nodal status were significant prognostic factors for local control. Tumour size and FIGO stage were significant for overall survival. In a multivariate analysis stratified by centre, only tumour size above 5 cm and lower pretreatment haemoglobin predicted poorer overall survival among FIGO stage, nodal involvement, tumour size, pretreatment haemoglobin dichotomized at 12 g/dl and pimo 1, pimo 4 and HP5 as continuous variables. Conclusion: Neither Eppendorf nor pimonidazole should be dismissed based on the current results. However, further investigations are needed to readdress the hypotheses of the current study having optimized statistical designs, and a population of sufficient size treated more homogenously following rigorous protocols. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available